Bright Minds Biosciences Inc. — Form 20-F Summary
Reporting period: Fiscal year ended September 30, 2021, compared primarily with the year ended September 30, 2020. This is an annual report, not a quarterly filing. Financial amounts are in Canadian dollars unless otherwise indicated. The company is an early-stage biotechnology developer of selective serotonin-receptor therapeutics and has not generated revenue.
Financial performance and position
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | Nil | Nil |
| Net loss | $8,650,763 | $480,377 |
| Basic and diluted loss per share | $0.96 | $0.13 |
| Research and development expense | $6,313,988 | $354,852 |
| Net cash used in operating activities | $7,319,301 | $288,392 |
| Cash and cash equivalents at year-end | $19,760,015 | $799,929 |
| Working capital | $19,399,795 | $727,293 |
| Total assets | $20,040,368 | $880,216 |
| Total liabilities | $638,573 | $150,923 |
Gross profit and operating margins are not meaningful because the company had no revenue. The filing reports no long-term debt. Current liabilities were $638,573; operating lease obligations totaled $92,373, all due within one year.
Material changes and financing
- Net loss rose by about $8.17 million year over year as the company ramped up operations. R&D increased by about $5.96 million, the largest cost increase.
- Other notable FY2021 expenses included marketing, advertising and investor relations of $852,151; professional fees of $709,954; and share-based compensation of $880,615. A $154,099 foreign-exchange recovery partially offset expenses.
- Financing activities provided net cash of $26,055,600. The company’s March 2021 public offering generated gross proceeds of approximately $25.89 million through units comprising shares and warrants.
- At September 30, 2021, 11,834,361 common shares were outstanding. The filing reports 1,025,807 options and 3,974,204 warrants outstanding at that date; these instruments could contribute to dilution.
Business, outlook and risks
- The company is developing selective 5-HT2C, 5-HT2A and combined 5-HT2C/A drug candidates for conditions including epilepsy, substance-use disorders, binge-eating disorder, depression, PTSD and pain. Its disclosed program results are preclinical; no product candidate had regulatory approval.
- Management expected continued losses and negative operating cash flow in FY2022. It stated that existing funds were expected to support operations for the next 12 months, while also anticipating further financing and warning that failure to raise acceptable capital could force a reduction or cessation of operations. No detailed numeric revenue or earnings guidance is provided.
- Key risks include early-stage drug development and clinical-trial failure or delay, regulatory approval uncertainty, no established revenue, ongoing cash burn and dependence on future financing, potential shareholder dilution, and reliance on third-party research and manufacturing. COVID-19 could disrupt external laboratories; management said it had no specific known COVID-related impact on disclosed milestones as of the report date, but the broader effects were uncertain.
- The company licensed university-owned patent rights in April 2021 in exchange for cash and 63,000 shares, with additional royalties, milestone payments and minimum annual royalties under specified conditions. The filing reports no material legal proceedings.
- The audited IFRS financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective as of September 30, 2021; the auditor did not provide an attestation on internal controls.
Important facts for investors to verify
- Cash burn, actual spending and financing needs against management’s stated 12-month funding expectation and FY2022 outlook.
- Progress from preclinical studies to regulatory filings and human trials, including safety, efficacy and timelines.
- Current cash, liabilities and lease commitments, and any subsequent financing or material change in liquidity.
- Fully diluted share count and the terms, vesting, exercise and potential dilution from outstanding options, warrants and restricted share units.
- License obligations, intellectual-property status and any changes to research partnerships, external laboratory access or development plans.